biOasis Technologies entered into a research and evaluation agreement with MedImmune, the biologics arm of AstraZeneca. Under the terms of the collaboration, biOasis will conduct certain experiments at MedImmune’s expense with the objective of demonstrating that biOasis’s Transcend™ technology can deliver to the brain compounds of interest to MedImmune.
“The work we have done to date on Transcend and the milestones we have achieved all support driving us to agreements such as the one we are announcing today. We look forward to working with MedImmune to successfully achieve the objectives set out in agreement,” said Rob Hutchison, CEO of biOasis.
Transcend is a carrier for delivery of therapeutic agents across the blood-brain barrier. By commercializing Transcend, biOasis will enable the routine treatment of a variety of clinically challenging CNS conditions.
biOasis signed a similar agreement with Abbott earlier this year and with Shire Human Genetic Therapies last year.